---
provider: falcon
model: Edison Scientific Literature
cached: false
start_time: '2025-12-27T23:42:52.944524'
end_time: '2025-12-27T23:46:41.086412'
duration_seconds: 228.14
template_file: templates/gene_research_go_focused.md
template_variables:
  organism: human
  gene_id: MAD2L1
  gene_symbol: MAD2L1
  uniprot_accession: Q13257
  protein_description: 'RecName: Full=Mitotic spindle assembly checkpoint protein
    MAD2A; Short=HsMAD2; AltName: Full=Mitotic arrest deficient 2-like protein 1;
    Short=MAD2-like protein 1;'
  gene_info: Name=MAD2L1; Synonyms=MAD2;
  organism_full: Homo sapiens (Human).
  protein_family: Belongs to the MAD2 family. .
  protein_domains: HORMA_dom. (IPR003511); HORMA_dom_sf. (IPR036570); Mad2-like. (IPR045091);
    HORMA (PF02301)
provider_config:
  timeout: 600
  max_retries: 3
  parameters:
    allowed_domains: []
    temperature: 0.1
citation_count: 15
---

## Question

# Gene Research for Functional Annotation

## ⚠️ CRITICAL: Gene/Protein Identification Context

**BEFORE YOU BEGIN RESEARCH:** You MUST verify you are researching the CORRECT gene/protein. Gene symbols can be ambiguous, especially for less well-characterized genes from non-model organisms.

### Target Gene/Protein Identity (from UniProt):
- **UniProt Accession:** Q13257
- **Protein Description:** RecName: Full=Mitotic spindle assembly checkpoint protein MAD2A; Short=HsMAD2; AltName: Full=Mitotic arrest deficient 2-like protein 1; Short=MAD2-like protein 1;
- **Gene Information:** Name=MAD2L1; Synonyms=MAD2;
- **Organism (full):** Homo sapiens (Human).
- **Protein Family:** Belongs to the MAD2 family. .
- **Key Domains:** HORMA_dom. (IPR003511); HORMA_dom_sf. (IPR036570); Mad2-like. (IPR045091); HORMA (PF02301)

### MANDATORY VERIFICATION STEPS:

1. **Check if the gene symbol "MAD2L1" matches the protein description above**
2. **Verify the organism is correct:** Homo sapiens (Human).
3. **Check if protein family/domains align with what you find in literature**
4. **If you find literature for a DIFFERENT gene with the same or similar symbol, STOP**

### If Gene Symbol is Ambiguous or You Cannot Find Relevant Literature:

**DO NOT PROCEED WITH RESEARCH ON A DIFFERENT GENE.** Instead:
- State clearly: "The gene symbol 'MAD2L1' is ambiguous or literature is limited for this specific protein"
- Explain what you found (e.g., "Found extensive literature on a different gene with the same symbol in a different organism")
- Describe the protein based ONLY on the UniProt information provided above
- Suggest that the protein function can be inferred from domain/family information

### Research Target:

Please provide a comprehensive research report on the gene **MAD2L1** (gene ID: MAD2L1, UniProt: Q13257) in human.

The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.

You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.

We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.

We are interested in where in or outside the cell the gene product carries out its function.

We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.

Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.

## Output

Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on:
1. Key concepts and definitions with current understanding
2. Recent developments and latest research (prioritize 2023-2024 sources)
3. Current applications and real-world implementations
4. Expert opinions and analysis from authoritative sources
5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available.
Always prioritize recent, authoritative sources and provide specific citations for all major claims.

# Gene Research for Functional Annotation

## ⚠️ CRITICAL: Gene/Protein Identification Context

**BEFORE YOU BEGIN RESEARCH:** You MUST verify you are researching the CORRECT gene/protein. Gene symbols can be ambiguous, especially for less well-characterized genes from non-model organisms.

### Target Gene/Protein Identity (from UniProt):
- **UniProt Accession:** Q13257
- **Protein Description:** RecName: Full=Mitotic spindle assembly checkpoint protein MAD2A; Short=HsMAD2; AltName: Full=Mitotic arrest deficient 2-like protein 1; Short=MAD2-like protein 1;
- **Gene Information:** Name=MAD2L1; Synonyms=MAD2;
- **Organism (full):** Homo sapiens (Human).
- **Protein Family:** Belongs to the MAD2 family. .
- **Key Domains:** HORMA_dom. (IPR003511); HORMA_dom_sf. (IPR036570); Mad2-like. (IPR045091); HORMA (PF02301)

### MANDATORY VERIFICATION STEPS:

1. **Check if the gene symbol "MAD2L1" matches the protein description above**
2. **Verify the organism is correct:** Homo sapiens (Human).
3. **Check if protein family/domains align with what you find in literature**
4. **If you find literature for a DIFFERENT gene with the same or similar symbol, STOP**

### If Gene Symbol is Ambiguous or You Cannot Find Relevant Literature:

**DO NOT PROCEED WITH RESEARCH ON A DIFFERENT GENE.** Instead:
- State clearly: "The gene symbol 'MAD2L1' is ambiguous or literature is limited for this specific protein"
- Explain what you found (e.g., "Found extensive literature on a different gene with the same symbol in a different organism")
- Describe the protein based ONLY on the UniProt information provided above
- Suggest that the protein function can be inferred from domain/family information

### Research Target:

Please provide a comprehensive research report on the gene **MAD2L1** (gene ID: MAD2L1, UniProt: Q13257) in human.

The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.

You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.

We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.

We are interested in where in or outside the cell the gene product carries out its function.

We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.

Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.

Research plan status: Identity verification completed; literature gathered; synthesizing findings into a focused functional annotation emphasizing 2023–2024 advances and mechanistic precision.

Executive summary
MAD2L1 (UniProt Q13257) encodes human MAD2A/MAD2, a HORMA-domain protein of the MAD2 family that is a core effector of the spindle assembly checkpoint (SAC). MAD2 cycles between open (O-MAD2) and closed (C-MAD2) conformations, binds MAD1 at unattached kinetochores to catalyze CDC20: MAD2 assembly, and contributes to the mitotic checkpoint complex (MCC) that inhibits APC/C–CDC20 to delay anaphase until proper kinetochore–microtubule attachment is achieved. Remodeling by p31comet (MAD2L1BP) and the AAA+ ATPase TRIP13 converts MAD2 to O-MAD2 and disassembles MCC to allow mitotic exit. Dysregulation of MAD2L1 is implicated in cancer biology and therapy responses. Recent studies refine how kinetochores catalyze MCC assembly and how MAD1 flexibility accelerates CDC20:MAD2 formation. (henriques2024exploringtheclinical pages 11-13, sethi2025interplayofkinetochores pages 20-23, chen2023thestructuralflexibility pages 12-15, leitch2024investigatingtherole pages 226-228, scarberry2025investigatingnterminalregulation pages 95-99, scarberry2025investigatingnterminalregulation pages 99-103)

1) Identity, key concepts, and definitions
- Identity verification: Human MAD2L1 (also MAD2A/MAD2) is a HORMA-domain protein in the MAD2 family, a canonical component of the SAC that binds CDC20 and participates in MCC assembly to inhibit APC/C. Multiple sources explicitly place MAD2 within the HORMA family and as a SAC effector, consistent with UniProt Q13257, Homo sapiens. (scarberry2025investigatingnterminalregulation pages 95-99, scarberry2025investigatingnterminalregulation pages 99-103)
- HORMA domain and conformational states: MAD2 is metamorphic with two native topologies—open (O-MAD2) and closed (C-MAD2). C-MAD2 is the active checkpoint form that binds ligands bearing a MAD2-interacting motif (e.g., CDC20); O-MAD2 can be templated at kinetochores to convert into C-MAD2. (sethi2025interplayofkinetochores pages 20-23, scarberry2025investigatingnterminalregulation pages 95-99, scarberry2025investigatingnterminalregulation pages 99-103)
- Template model of MAD2 activation: A MAD1:C-MAD2 core at unattached kinetochores recruits O-MAD2 and catalyzes its conformational conversion and assembly with CDC20, initiating MCC formation. (henriques2024exploringtheclinical pages 11-13, sethi2025interplayofkinetochores pages 20-23)

2) Core molecular function and pathway placement
- SAC effector function: CDC20:MAD2 associates with BUBR1:BUB3 to form the MCC, which inhibits APC/C–CDC20, thereby preventing anaphase onset until all kinetochores achieve proper microtubule attachment. (leitch2024investigatingtherole pages 226-228, pun2025roleofspindle pages 11-13)
- Conformational switching governs function: O-MAD2 conversion to C-MAD2 is central to CDC20 capture; the reverse remodeling to O-MAD2 promotes checkpoint silencing. (sethi2025interplayofkinetochores pages 20-23, leitch2024investigatingtherole pages 226-228)
- APC/C inhibition and release: MCC binding suppresses APC/C–CDC20 ubiquitylation activity; p31comet and TRIP13 subsequently promote MCC disassembly and MAD2 remodeling to relieve APC/C inhibition for mitotic exit. (henriques2024exploringtheclinical pages 11-13, leitch2024investigatingtherole pages 226-228)

3) Subcellular localization and dynamics
- Kinetochore-centric activation: At unattached kinetochores, MAD1:C-MAD2 forms a catalytic platform that recruits cytosolic O-MAD2, increasing the local rate of CDC20:MAD2 formation; Mps1-dependent kinetochore signaling positions and activates this platform. (sethi2025interplayofkinetochores pages 20-23)
- Cytosolic pools and potential interphase sites: A cytosolic O-MAD2 pool supports rapid templated conversion; some studies propose additional sites (e.g., nuclear pore complexes) facilitating early MCC assembly, though this remains under active investigation. (chen2023thestructuralflexibility pages 12-15)
- Other compartments (contextual): Reports link a fraction of MAD2 to PML nuclear bodies and interphase structures in specialized contexts, especially under overexpression or stress, though this is not its primary site of SAC action. (pun2025roleofspindle pages 11-13)

4) Regulation of MAD2L1 activity
- p31comet (MAD2L1BP/CMT2) and TRIP13: p31comet binds C‑MAD2 in a conformation-specific manner to antagonize MAD2; together with the AAA+ ATPase TRIP13, it extracts MAD2 from the MCC and remodels MAD2 to O‑MAD2, driving checkpoint silencing. Dysregulated or elevated p31comet can promote mitotic slippage and drug resistance in cancer models. (henriques2024exploringtheclinical pages 11-13, leitch2024investigatingtherole pages 226-228, scarberry2025investigatingnterminalregulation pages 99-103)
- Kinetochores as catalysts: Kinetochore scaffolds co-orient MAD1:MAD2 with BUB1:BUB3 and CDC20 to accelerate CDC20:MAD2 and MCC assembly, explaining rapid SAC signal generation in vivo. (sethi2025interplayofkinetochores pages 20-23)
- MAD1 structural flexibility: MAD1 contains a hinge that enables a folded conformation of the MAD1:MAD2 complex; this flexibility facilitates “catalytic” presentation of CDC20’s MAD2-interacting motif to MAD2 and accelerates MCC assembly. Disrupting the hinge slows MCC formation and weakens SAC signaling. (bioRxiv, 2023; https://doi.org/10.1101/2022.06.29.498198). (chen2023thestructuralflexibility pages 12-15)
- Additional post-translational control: Phosphoregulation at kinetochores and of SAC components modulates recruitment and silencing dynamics; broader reviews compiled in 2024 reiterate p31comet/TRIP13’s central role in MAD2 remodeling. (leitch2024investigatingtherole pages 226-228)

5) Recent developments and latest research (priority 2023–2024)
- MAD1 flexibility accelerates MCC assembly: A 2023 mechanistic study proposes a “knitting/folding” model in which MAD1’s hinge enhances the rate-limiting CDC20:MAD2 step, integrating structural modeling, biochemical reconstitution, and live-cell assays. (bioRxiv, 2023-07; https://doi.org/10.1101/2022.06.29.498198). (chen2023thestructuralflexibility pages 12-15)
- Kinetochore-enabled catalysis of MCC: 2024/2025 reconstitutions emphasize kinetochores as catalytic hubs that co-concentrate MAD1:MAD2 and BUB1:BUB3 with CDC20 to drive rapid MCC assembly at near-physiological concentrations, refining the template model with spatial organization principles. (bioRxiv preprint history 2024-06; https://doi.org/10.1101/2024.06.09.598118). (sethi2025interplayofkinetochores pages 20-23)
- p31comet/TRIP13 in checkpoint silencing and cancer: 2024 commentary and dataset-driven analyses reiterate that p31comet binds MAD2 conformation-specifically and, with TRIP13, disassembles the MCC and converts C‑MAD2→O‑MAD2; these activities influence mitotic slippage and antimitotic drug sensitivity in tumors. (Scientific Letters, 2024-07; https://doi.org/10.48797/sl.2024.266). (henriques2024exploringtheclinical pages 11-13)
- Integrative phosphoregulation reviews (2024): Current overviews underscore how kinetochore signaling and post-translational control (Mps1, BUB1 positioning of MAD1, APC/C–CDC20 regulation) intersect with MAD2 conformational switching to tune SAC strength and timing. (2024; journal not specified in excerpt). (leitch2024investigatingtherole pages 226-228)

6) Current applications and real-world implementations
- Translational cancer insights: Elevated MAD2/MAD2L1 pathway activity and altered p31comet/TRIP13 function are linked to cancer proliferation and therapy responses; checkpoint silencing via p31comet/TRIP13 can contribute to mitotic slippage and resistance to antimitotics, suggesting that modulating MAD2 remodeling may sensitize tumors. Analyses leveraging TCGA/UALCAN pipelines highlight these regulatory axes in clinical datasets. (henriques2024exploringtheclinical pages 11-13)
- Probe compounds and strategies: Targeting the CDC20:MAD2 interface and modulating p31comet/TRIP13 activity are active experimental strategies; multiple lines of evidence suggest these nodes influence MCC stability, checkpoint duration, and drug sensitivity. (scarberry2025investigatingnterminalregulation pages 99-103, henriques2024exploringtheclinical pages 11-13)

7) Expert opinions and authoritative perspectives
- Conceptual consensus: The field converges on a template-based mechanism in which MAD1:C‑MAD2 at unattached kinetochores catalyzes MAD2 activation and CDC20 capture, while p31comet/TRIP13 reverse this to terminate signaling—a balanced cycle that ensures fidelity yet allows rapid anaphase onset once attachments are complete. (sethi2025interplayofkinetochores pages 20-23, leitch2024investigatingtherole pages 226-228, scarberry2025investigatingnterminalregulation pages 99-103)
- Mechanistic nuance: New data argue that macromolecular flexibility (MAD1 hinge) and kinetochore microenvironments are as critical as binary affinities for achieving physiological MCC assembly rates, highlighting the importance of spatial organization and conformational catalysis in SAC control. (chen2023thestructuralflexibility pages 12-15, sethi2025interplayofkinetochores pages 20-23)

8) Statistics and quantitative observations from recent studies
- Rate-limiting step: Multiple recent works reiterate that CDC20:MAD2 formation is the rate-limiting step of MCC assembly; accelerating this step via MAD1 flexibility or kinetochore scaffolding produces measurable increases in MCC assembly rate in vitro and delays anaphase onset in cells when impaired—quantitative details are presented in the cited preprints but converge on a significant rate effect of the MAD1 hinge and kinetochore co-orientation. (chen2023thestructuralflexibility pages 12-15, sethi2025interplayofkinetochores pages 20-23)
- Clinical data resources: 2024 analyses referencing TCGA/UALCAN highlight associations between p31comet/MAD2 pathway components and clinical outcomes; specific hazard ratios and effect sizes depend on tumor type and dataset and are reported within those resources. (henriques2024exploringtheclinical pages 11-13)

9) Clarifications on symbol/organism and domain/family verification
- Symbol and organism: All evidence pertains to human MAD2L1 (MAD2/MAD2A) and its canonical SAC role. No conflicting non-human or alternative-gene-symbol literature was used for functional assertions here. (scarberry2025investigatingnterminalregulation pages 95-99, scarberry2025investigatingnterminalregulation pages 99-103)
- Family/domain: MAD2 is a prototypical HORMA-domain protein whose conformational switching underlies its function—fully consistent with the UniProt description, protein family assignment, and domain architecture. (scarberry2025investigatingnterminalregulation pages 95-99, scarberry2025investigatingnterminalregulation pages 99-103)

Key references with URLs and dates
- Henriques AC et al. Exploring the clinical relevance of p31comet in HNSCC; highlights p31comet–MAD2–TRIP13 regulation and clinical implications. Scientific Letters. 2024-07. URL: https://doi.org/10.48797/sl.2024.266 (henriques2024exploringtheclinical pages 11-13)
- Sethi S et al. Interplay of kinetochores and catalysts drives rapid MCC assembly; kinetochore-mediated catalysis of CDC20:MAD2. bioRxiv. Version history includes 2024-06. URL: https://doi.org/10.1101/2024.06.09.598118 (sethi2025interplayofkinetochores pages 20-23)
- Chen C et al. The structural flexibility of MAD1 facilitates MCC assembly; MAD1 hinge accelerates CDC20:MAD2 formation. bioRxiv. 2023-07. URL: https://doi.org/10.1101/2022.06.29.498198 (chen2023thestructuralflexibility pages 12-15)
- Leitch I. Investigating the role of phosphatases in regulation of mitosis; succinct synthesis of MAD2 conformational control, p31comet/TRIP13, and kinetochore phosphoregulation (2024). URL: not provided in excerpt (leitch2024investigatingtherole pages 226-228)
- Scarberry L. Investigating N-terminal regulation of p31Comet in Mitosis; collates MAD2 HORMA identity, p31comet interactions, TRIP13-driven remodeling, and disease links. 2025. URL: not provided in excerpt (scarberry2025investigatingnterminalregulation pages 95-99, scarberry2025investigatingnterminalregulation pages 99-103)
- Pun R, North BJ. Role of SAC proteins in gametogenesis and embryogenesis; summarizes SAC/MCC (MAD2, BUBR1, BUB3, CDC20) biology and phenotypes. Frontiers in Cell and Developmental Biology. 2025-01. URL: https://doi.org/10.3389/fcell.2024.1491394 (pun2025roleofspindle pages 11-13)

Limitations and open questions
- While 2023–2024 mechanistic advances clarify MAD1-enabled catalysis and kinetochore co-organization, high-resolution structural snapshots of human CDC20:MAD2 within MCC–APC/C at these specific timepoints were not directly cited here and should be integrated from complementary structural studies. (leitch2024investigatingtherole pages 226-228)
- Quantitative clinical statistics (e.g., tumor-type–specific hazard ratios for MAD2L1) vary across datasets and were not enumerated in the excerpts; readers should consult the referenced resources for study-specific effect sizes. (henriques2024exploringtheclinical pages 11-13)

Conclusions
MAD2L1 encodes a human HORMA-domain protein whose conformational plasticity powers the SAC. At unattached kinetochores, MAD1:C‑MAD2 templates O‑MAD2 activation and CDC20 capture, funneling into MCC formation that inhibits APC/C–CDC20 and restrains anaphase. p31comet and TRIP13 reverse this state by remodeling C‑MAD2 to O‑MAD2 and disassembling MCC, licensing mitotic exit. Recent work emphasizes how MAD1’s structural flexibility and kinetochore catalytic organization accelerate the rate-limiting CDC20:MAD2 step to achieve timely and robust checkpoint control; dysregulation of these axes contributes to tumorigenesis and therapy responses, underscoring translational opportunities at the MAD2–p31comet–TRIP13 and CDC20:MAD2 interfaces. (sethi2025interplayofkinetochores pages 20-23, chen2023thestructuralflexibility pages 12-15, henriques2024exploringtheclinical pages 11-13, leitch2024investigatingtherole pages 226-228, scarberry2025investigatingnterminalregulation pages 99-103)

References

1. (henriques2024exploringtheclinical pages 11-13): Ana C. Henriques Henriques, João P. N. Silva, Bárbara Pinto, Patricia M. A. Silva, and Hassan Bousbaa. Exploring the clinical relevance of p31comet in head and neck squamous cell carcinoma through ualcan database analysis. Scientific Letters, Jul 2024. URL: https://doi.org/10.48797/sl.2024.266, doi:10.48797/sl.2024.266. This article has 1 citations.

2. (sethi2025interplayofkinetochores pages 20-23): Suruchi Sethi, Valentina Piano, Sabrina Ghetti, Verena Cmentowski, Patricia Stege, and Andrea Musacchio. Interplay of kinetochores and catalysts drives rapid assembly of the mitotic checkpoint complex. bioRxiv, Jun 2025. URL: https://doi.org/10.1101/2024.06.09.598118, doi:10.1101/2024.06.09.598118. This article has 3 citations and is from a poor quality or predatory journal.

3. (chen2023thestructuralflexibility pages 12-15): Chu Chen, Valentina Piano, Amal Alex, Simon J. Y. Han, Pim J Huis In ’t Veld, Babhrubahan Roy, Andrea Musacchio, and Ajit P. Joglekar. The structural flexibility of mad1 facilitates the assembly of the mitotic checkpoint complex. BioRxiv, Jul 2023. URL: https://doi.org/10.1101/2022.06.29.498198, doi:10.1101/2022.06.29.498198. This article has 15 citations and is from a poor quality or predatory journal.

4. (leitch2024investigatingtherole pages 226-228): I Leitch. Investigating the role of phosphatases in the regulation of mitosis. Unknown journal, 2024.

5. (scarberry2025investigatingnterminalregulation pages 95-99): L Scarberry. Investigating n-terminal regulation of p31comet in mitosis. Unknown journal, 2025.

6. (scarberry2025investigatingnterminalregulation pages 99-103): L Scarberry. Investigating n-terminal regulation of p31comet in mitosis. Unknown journal, 2025.

7. (pun2025roleofspindle pages 11-13): Renju Pun and Brian J. North. Role of spindle assembly checkpoint proteins in gametogenesis and embryogenesis. Frontiers in Cell and Developmental Biology, Jan 2025. URL: https://doi.org/10.3389/fcell.2024.1491394, doi:10.3389/fcell.2024.1491394. This article has 2 citations and is from a poor quality or predatory journal.

## Citations

1. sethi2025interplayofkinetochores pages 20-23
2. chen2023thestructuralflexibility pages 12-15
3. pun2025roleofspindle pages 11-13
4. leitch2024investigatingtherole pages 226-228
5. henriques2024exploringtheclinical pages 11-13
6. scarberry2025investigatingnterminalregulation pages 95-99
7. scarberry2025investigatingnterminalregulation pages 99-103
8. https://doi.org/10.1101/2022.06.29.498198
9. https://doi.org/10.1101/2024.06.09.598118
10. https://doi.org/10.48797/sl.2024.266
11. https://doi.org/10.3389/fcell.2024.1491394
12. https://doi.org/10.48797/sl.2024.266,
13. https://doi.org/10.1101/2024.06.09.598118,
14. https://doi.org/10.1101/2022.06.29.498198,
15. https://doi.org/10.3389/fcell.2024.1491394,